Results 221 to 230 of about 384,012 (260)

Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Journal of Cardiac Failure
BACKGROUND In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
P. García-Pavía, A. Kristen, B. Drachman, M. Carlsson, L. Amass, F. Angeli, Mathew S. Maurer   +6 more
semanticscholar   +1 more source

Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging

Journal of Clinical Medicine
Amyloidosis is an infiltrative disease that may cause cardiomyopathy if the precursor protein that misfolds and forms the amyloid is transthyretic or plasma abnormal light chains.
Georgios Tziomalos, T. Zegkos, Eleftheria Baltagianni, M. Bazmpani, P. Exadaktylou, D. Parcharidou, Thomas D. Gossios, A. Doumas, Theodoros D. Karamitsos, Vasileios Vassilikos, Georgios K Efthimiadis, A. Ziakas, Vasileios Kamperidis   +12 more
semanticscholar   +1 more source

Current and emerging treatment options for transthyretin amyloid cardiomyopathy

Heart
Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the heart and nervous system, leading to organ dysfunction.
G. Vergaro, Y. F. Ferrari Chen, A. Ioannou, G. Panichella, V. Castiglione, A. Aimo, M. Emdin, Marianna Fontana   +7 more
semanticscholar   +1 more source

Amyloid Cardiomyopathy in the Emergency Department

The Journal of Emergency Medicine, 2019
Cardiac amyloidosis is an underdiagnosed cause of restrictive cardiomyopathy resulting from the infiltration of the myocardium by amyloid proteins.We report the case of an 83-year-old woman who presented with increasing dyspnea and lower-extremity swelling. She reported a medical history of unspecified heart failure.
Mauricio Baca, Mark Newberry
openaire   +2 more sources

Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

European Journal of Nuclear Medicine and Molecular Imaging
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequent concomitant condition in patients with severe aortic stenosis (AS), yet it often remains undetected.
I. Shiri, S. Balzer, Giovanni Baj, B. Bernhard, Moritz Hundertmark, A. Bakula, M. Nakase, D. Tomii, Giulia Barbati, S. Dobner, Waldo Valenzuela, A. Rominger, F. Caobelli, G. Siontis, J. Lanz, T. Pilgrim, Stephan Windecker, S. Stortecky, Christoph Gräni   +18 more
semanticscholar   +1 more source

Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy

JACC: Advances
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression ...
T. Kao, Yi-Hsin Hung, A. Yu, M. Cheng, M. Su, C. Chao, C. Tsai, Yen-Hung Lin   +7 more
semanticscholar   +1 more source

Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy.

American Journal of Cardiology
Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) benefit from disease-modifying agents such as tafamidis. However, the survival benefit of tafamidis in elderly patients (age ≥80 years) is not reported.
Abdullah Sarkar, Alejandro Sanchez-Nadales, S. Kunutsor, Mazen A. Hanna, Craig R. Asher, David Wolinsky   +5 more
semanticscholar   +1 more source

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: A scoping review.

European Heart Journal - Cardiovascular Pharmacotherapy
AIMS Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies
Shafi Rehman, Shameera Shaik Masthan, Ramzi Ibrahim, H. N. Pham, Danial Hassan, Fahad Ahmad, M. S. Asif, Ahmad Safdar, Zain Anwar, S. Raza, Preethi William   +10 more
semanticscholar   +1 more source

The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors?

European Journal of Heart Failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively common cause of heart failure (HF) that results from accumulation of amyloid, derived from transthyretin (TTR), a protein produced by the liver, in the myocardial extracellular space.
A. Porcari, Marianna Fontana
semanticscholar   +1 more source

Coexisting transthyretin and atrial natriuretic peptide amyloid on left atrium in transthyretin amyloid cardiomyopathy.

Journal of Cardiology Cases
Atrial amyloidosis is primarily caused by atrial natriuretic peptide (ANP) amyloid deposition. The main precursor protein causing cardiac amyloidosis is transthyretin (TTR), also known as TTR amyloid cardiomyopathy (ATTR-CM).
N. Kuyama, S. Takashio, Kosuke Nakamura, K. Nishigawa, S. Hanatani, Hiroki Usuku, E. Yamamoto, Mitsuharu Ueda, Toshihiro Fukui, Kenichi Tsujita   +9 more
semanticscholar   +1 more source